▶ 調査レポート

脂質疾患治療薬の世界市場分析・規模・シェア・成長・動向・予測:薬物種類別(アトルバスタチン、フルバスタチン、ロスバスタチン、シンバスタチン、その他)、流通経路別(小売薬局、病院内薬局、オンライン薬局)、適応症別(家族性複合型高脂血症、家族性欠陥アポリポ蛋白B血症、3型高脂血症、家族性高トリグリセリド血症、ヘテロ接合性家族性高コレステロール血症、その他)

• 英文タイトル:Lipid Disorder Treatment Market (Drug Type- Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, and Other Drugs; Distribution Channel- Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies; Indication- Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, and Other Indications) - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026
• レポートコード:TPM-B04233
• 出版社/出版日:Transparency Market Research / 2018年3月
• レポート形態:英文、PDF、170ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥614,270 (USD5,795)▷ お問い合わせ
  Multi User¥932,270 (USD8,795)▷ お問い合わせ
  Global Site License¥1,250,270 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、脂質疾患治療薬の世界市場について調べ、脂質疾患治療薬の世界規模、市場動向、市場環境、薬物種類別(アトルバスタチン、フルバスタチン、ロスバスタチン、シンバスタチン、その他)分析、流通経路別(小売薬局、病院内薬局、オンライン薬局)分析、適応症別(家族性複合型高脂血症、家族性欠陥アポリポ蛋白B血症、3型高脂血症、家族性高トリグリセリド血症、ヘテロ接合性家族性高コレステロール血症、その他)
分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。

・序文・調査範囲・調査手法
・エグゼクティブサマリー
・脂質疾患治療薬の世界市場動向
・脂質疾患治療薬の世界市場環境
・脂質疾患治療薬の世界市場規模
・脂質疾患治療薬の世界市場規模:薬物種類別(アトルバスタチン、フルバスタチン、ロスバスタチン、シンバスタチン、その他)
・脂質疾患治療薬の世界市場規模:流通経路別(小売薬局、病院内薬局、オンライン薬局)
・脂質疾患治療薬の世界市場規模:適応症別(家族性複合型高脂血症、家族性欠陥アポリポ蛋白B血症、3型高脂血症、家族性高トリグリセリド血症、ヘテロ接合性家族性高コレステロール血症、その他)

・脂質疾患治療薬の世界市場:地域別市場規模・分析
・脂質疾患治療薬の北米市場規模・予測
・脂質疾患治療薬のアメリカ市場規模・予測
・脂質疾患治療薬の中南米市場規模・予測
・脂質疾患治療薬のヨーロッパ市場規模・予測
・脂質疾患治療薬のアジア市場規模・予測
・脂質疾患治療薬の日本市場規模・予測
・脂質疾患治療薬の中国市場規模・予測
・脂質疾患治療薬のインド市場規模・予測
・脂質疾患治療薬のアフリカ市場規模・予測
・競争状況・関連企業情報

Extensive research report on global lipid disorders treatment market skilfully crafted by Transparency Market Research depicts the current as well as future scenario of various drugs used to treat lipid disorders. The research study includes analysis on key developments that are shaping the demand for advanced drugs for lipid disorders. A detailed qualitative assessment has been covered in this research report that delivers value by offering weighted analysis on restraints, drivers, trends and opportunities in the global market. Readers of the report can benefit from the actionable intelligence provided in this research report that is likely to impact the growth of the global market in the coming years.

An in-depth market assessment on the cost structure of various drugs used in the treatment of lipid disorders, detailed supply chain analysis, analysis on sourcing of raw material and various service providers has been covered for the reader’s perusal. Such an intense market analysis can support the reader’s decision in making expansion plans, implementing key strategies as well as tapping new regional markets and developing new products. Moreover, scrutiny on various lipid disorder treatments also covers the supply and demand scenario at a global level. The reader of the report can expect a high level analysis on major market aspects impacting the consumption and sales of several lipid disorder treating drugs.

Detailed market segmentation carried out on this market covers every angle offering the readers with insights associated with sluggish or lucrative growth avenues. Detailed segment wise analysis offers the readers with market intelligence that can be used to distinguish between high growing, moderate growing and slow growing regions. New revenue pockets can be identified through the analysis done in this research report. The research study analyzes each and every segment of the market across key regions in the globe to portray a complete market understanding for a forecast period of nine years. The research study also covers historical data and current market scenario.

Competitive landscape

The research study on global lipid disorders treatment market includes a comprehensive competitive assessment that offers key insights on major pharmaceutical companies involved in the manufacturing of drugs for treating lipid disorders. Business strategies, market entry strategies, product portfolios of these key players has been covered in this research report. A complete market intelligence package is promised by Transparency Market Research by including the section on competitive dashboard that tracks the activities of various companies, thus assisting the reader in sating key tactics to gain competitive advantage in the years to come. Additionally, key financials, revenue shares and profit analysis across range of products is included in this section. This information can assist the readers in analyzing weaknesses, threats, opportunities and strengths in the market.

The information on various segments, regions and competitors covered in this research report has been compiled using extensive secondary and in depth primary research modules. Moreover, investor and press releases, trade associations and industry databases have been churned to gather additional information thus presenting a portraying a complete market scenario. The process carried out during research ensures a high accuracy data and statistics, thus increasing the credibility of the research study.

Key Facts

Readers can benefit from the comprehensive 360 degree market outlook that covers key insights of the global market along with future market projections. Additionally, the research report can support upcoming businesses in gaining hold in the global market by identifying revenue pockets across the globe. Moreover, the systematic report structure and skilful statistical presentations make this research report user friendly and the analysis and insights can be used to formulate business strategies.

レポート目次

1. Global Outlook

2. Global Lipid Disorder Treatment Market – Executive Summary

3. Global Lipid Disorder Treatment Market Overview
3.1. Introduction
3.1.1. Global Lipid Disorder Treatment Market Taxonomy
3.1.2. Global Lipid Disorder Treatment Market Definition
3.2. Global Lipid Disorder Treatment Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Lipid Disorder Treatment Market Y-o-Y Growth
3.3. Global Lipid Disorder Treatment Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. Porte’s Five Forces Analysis
3.7. Desirable Lipid Levels in Adults
3.8. Limiting Fat and Cholesterol in the Diet
3.9. A Practical Approach to a Low-Cholesterol, Low-Saturated Fat Diet
3.10. Cholesterol and Heart Disease By the Numbers
3.11. Screening for Elevated Cholesterol
3.12. Lifestyle Interventions
3.13. Treatment based on Group
3.14. PEST Analysis
3.15. Market Positioning and Behaviour Assessment
3.16. Investment Feasibility Index
3.17. Competitor Market Footprint Matrix
3.18. Key Participants Market Presence (Intensity Map) By Region

4. Global Lipid Disorder Treatment Market Analysis and Forecast 2012-2026
4.1. Global Lipid Disorder Treatment Market Size and Forecast By Drug Type, 2012-2026
4.1.1. Atorvastatin Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Fluvastatin Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Rosuvastatin Market Size and Forecast, 2012-2026
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Simvastatin Market Size and Forecast, 2012-2026
4.1.4.1. Revenue (US$ Mn) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.1.5. Pravastatin Market Size and Forecast, 2012-2026
4.1.5.1. Revenue (US$ Mn) Comparison, By Region
4.1.5.2. Market Share Comparison, By Region
4.1.5.3. Y-o-Y growth Comparison, By Region
4.1.6. Other Drugs Market Size and Forecast, 2012-2026
4.1.6.1. Revenue (US$ Mn) Comparison, By Region
4.1.6.2. Market Share Comparison, By Region
4.1.6.3. Y-o-Y growth Comparison, By Region
4.2. Global Lipid Disorder Treatment Market Size and Forecast By Distribution Channel, 2012-2026
4.2.1. Retail Pharmacies Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Hospital Pharmacies Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.2.3. Online Pharmacies Market Size and Forecast, 2012-2026
4.2.3.1. Revenue (US$ Mn) Comparison, By Region
4.2.3.2. Market Share Comparison, By Region
4.2.3.3. Y-o-Y growth Comparison, By Region
4.3. Global Lipid Disorder Treatment Market Size and Forecast By Indication, 2012-2026
4.3.1. Familial Combined Hyperlipidemia Market Size and Forecast, 2012-2026
4.3.1.1. Revenue (US$ Mn) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Familial Defective Apolipoprotein B-100 Market Size and Forecast, 2012-2026
4.3.2.1. Revenue (US$ Mn) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Familial Dysbetalipoproteinemia Market Size and Forecast, 2012-2026
4.3.3.1. Revenue (US$ Mn) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.3.4. Familial Hypertriglyceridemia Market Size and Forecast, 2012-2026
4.3.4.1. Revenue (US$ Mn) Comparison, By Region
4.3.4.2. Market Share Comparison, By Region
4.3.4.3. Y-o-Y growth Comparison, By Region
4.3.5. Heterozygous Familial Hypercholesterolemia Market Size and Forecast, 2012-2026
4.3.5.1. Revenue (US$ Mn) Comparison, By Region
4.3.5.2. Market Share Comparison, By Region
4.3.5.3. Y-o-Y growth Comparison, By Region
4.3.6. Other Indications Market Size and Forecast, 2012-2026
4.3.6.1. Revenue (US$ Mn) Comparison, By Region
4.3.6.2. Market Share Comparison, By Region
4.3.6.3. Y-o-Y growth Comparison, By Region

5. North America Lipid Disorder Treatment Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Drug Type
5.6. Revenue (US$ Mn) Comparison, By Distribution Channel
5.7. Revenue (US$ Mn) Comparison, By Indication

6. Latin America Lipid Disorder Treatment Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Drug Type
6.6. Revenue (US$ Mn) Comparison, By Distribution Channel
6.7. Revenue (US$ Mn) Comparison, By Indication

7. Europe Lipid Disorder Treatment Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Drug Type
7.6. Revenue (US$ Mn) Comparison, By Distribution Channel
7.7. Revenue (US$ Mn) Comparison, By Indication

8. Japan Lipid Disorder Treatment Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Drug Type
8.6. Revenue (US$ Mn) Comparison, By Distribution Channel
8.7. Revenue (US$ Mn) Comparison, By Indication

9. APEJ Lipid Disorder Treatment Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Drug Type
9.6. Revenue (US$ Mn) Comparison, By Distribution Channel
9.7. Revenue (US$ Mn) Comparison, By Indication

10. MEA Lipid Disorder Treatment Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Drug Type
10.6. Revenue (US$ Mn) Comparison, By Distribution Channel
10.7. Revenue (US$ Mn) Comparison, By Indication

11. Global Lipid Disorder Treatment Market Company Share, Competition Landscape and Company Profiles
11.1. Global Lipid Disorder Treatment Market Company Share Analysis
11.2. Global Lipid Disorder Treatment Market Competition Landscape
11.3. Global Lipid Disorder Treatment Market Company Profiles
11.3.1. Pfizer, Inc
11.3.2. Novartis AG
11.3.3. Astrazeneca Plc
11.3.4. Merck & Co.
11.3.5. Emcure Pharmaceuticals Ltd.
11.3.6. Ranbaxy Laboratories Ltd.
11.3.7. Teva Pharmaceuticals
11.3.8. Mylan Pharmaceuticals, Inc.
11.3.9. Kowa Pharmaceuticals America, Inc.
11.3.10. Glenmark Pharmaceuticals Ltd.
11.3.11. Sun Pharmaceuticals Industries Ltd.
11.3.12. Wockhardt Limited

12. Key Takeaways

13. Research Methodology

14. Disclaimer

List of Table

TABLE 1 Global Lipid Disorder Treatment Market Value (US$ Mn), 2012-2017
TABLE 2 Global Lipid Disorder Treatment Market Value (US$ Mn), 2018-2026
TABLE 3 Global Lipid Disorder Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Atorvastatin Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Atorvastatin Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Atorvastatin Segment Market Share, By Region 2012-2017
TABLE 7 Global Atorvastatin Segment Market Share, By Region 2018-2026
TABLE 8 Global Atorvastatin Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Fluvastatin Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Fluvastatin Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Fluvastatin Segment Market Share, By Region 2012-2017
TABLE 12 Global Fluvastatin Segment Market Share, By Region 2018-2026
TABLE 13 Global Fluvastatin Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Rosuvastatin Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Rosuvastatin Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Rosuvastatin Segment Market Share, By Region 2012-2017
TABLE 17 Global Rosuvastatin Segment Market Share, By Region 2018-2026
TABLE 18 Global Rosuvastatin Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Simvastatin Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Simvastatin Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Simvastatin Segment Market Share, By Region 2012-2017
TABLE 22 Global Simvastatin Segment Market Share, By Region 2018-2026
TABLE 23 Global Simvastatin Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Pravastatin Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Pravastatin Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Pravastatin Segment Market Share, By Region 2012-2017
TABLE 27 Global Pravastatin Segment Market Share, By Region 2018-2026
TABLE 28 Global Pravastatin Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Other Drugs Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Other Drugs Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Other Drugs Segment Market Share, By Region 2012-2017
TABLE 32 Global Other Drugs Segment Market Share, By Region 2018-2026
TABLE 33 Global Other Drugs Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 37 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 38 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 42 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 43 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 44 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 45 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 46 Global Online Pharmacies Segment Market Share, By Region 2012-2017
TABLE 47 Global Online Pharmacies Segment Market Share, By Region 2018-2026
TABLE 48 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 49 Global Familial Combined Hyperlipidemia Segment Value (US$ Mn), By Region 2012-2017
TABLE 50 Global Familial Combined Hyperlipidemia Segment Value (US$ Mn), By Region 2018-2026
TABLE 51 Global Familial Combined Hyperlipidemia Segment Market Share, By Region 2012-2017
TABLE 52 Global Familial Combined Hyperlipidemia Segment Market Share, By Region 2018-2026
TABLE 53 Global Familial Combined Hyperlipidemia Segment Y-o-Y, By Region 2017-2026
TABLE 54 Global Familial Defective Apolipoprotein B-100 Segment Value (US$ Mn), By Region 2012-2017
TABLE 55 Global Familial Defective Apolipoprotein B-100 Segment Value (US$ Mn), By Region 2018-2026
TABLE 56 Global Familial Defective Apolipoprotein B-100 Segment Market Share, By Region 2012-2017
TABLE 57 Global Familial Defective Apolipoprotein B-100 Segment Market Share, By Region 2018-2026
TABLE 58 Global Familial Defective Apolipoprotein B-100 Segment Y-o-Y, By Region 2017-2026
TABLE 59 Global Familial Dysbetalipoproteinemia Segment Value (US$ Mn), By Region 2012-2017
TABLE 60 Global Familial Dysbetalipoproteinemia Segment Value (US$ Mn), By Region 2018-2026
TABLE 61 Global Familial Dysbetalipoproteinemia Segment Market Share, By Region 2012-2017
TABLE 62 Global Familial Dysbetalipoproteinemia Segment Market Share, By Region 2018-2026
TABLE 63 Global Familial Dysbetalipoproteinemia Segment Y-o-Y, By Region 2017-2026
TABLE 64 Global Familial Hypertriglyceridemia Segment Value (US$ Mn), By Region 2012-2017
TABLE 65 Global Familial Hypertriglyceridemia Segment Value (US$ Mn), By Region 2018-2026
TABLE 66 Global Familial Hypertriglyceridemia Segment Market Share, By Region 2012-2017
TABLE 67 Global Familial Hypertriglyceridemia Segment Market Share, By Region 2018-2026
TABLE 68 Global Familial Hypertriglyceridemia Segment Y-o-Y, By Region 2017-2026
TABLE 69 Global Heterozygous Familial Hypercholesterolemia Segment Value (US$ Mn), By Region 2012-2017
TABLE 70 Global Heterozygous Familial Hypercholesterolemia Segment Value (US$ Mn), By Region 2018-2026
TABLE 71 Global Heterozygous Familial Hypercholesterolemia Segment Market Share, By Region 2012-2017
TABLE 72 Global Heterozygous Familial Hypercholesterolemia Segment Market Share, By Region 2018-2026
TABLE 73 Global Heterozygous Familial Hypercholesterolemia Segment Y-o-Y, By Region 2017-2026
TABLE 74 Global Other Indications Segment Value (US$ Mn), By Region 2012-2017
TABLE 75 Global Other Indications Segment Value (US$ Mn), By Region 2018-2026
TABLE 76 Global Other Indications Segment Market Share, By Region 2012-2017
TABLE 77 Global Other Indications Segment Market Share, By Region 2018-2026
TABLE 78 Global Other Indications Segment Y-o-Y, By Region 2017-2026
TABLE 79 North America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 80 North America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 81 North America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 82 North America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 83 North America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 84 North America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 85 North America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 86 North America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 87 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 88 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 89 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 90 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 91 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 92 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 93 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 94 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 95 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 96 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 97 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 98 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 99 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 100 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 101 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 102 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 103 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 104 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 105 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 106 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 107 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 108 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 109 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 110 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 111 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 112 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 113 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 114 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 115 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 116 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 117 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 118 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 119 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 120 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 121 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 122 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 123 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 124 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 125 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 126 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026


• 英文レポート名:Lipid Disorder Treatment Market (Drug Type- Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, and Other Drugs; Distribution Channel- Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies; Indication- Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, and Other Indications) - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026
• 日本語訳:脂質疾患治療薬の世界市場分析・規模・シェア・成長・動向・予測:薬物種類別(アトルバスタチン、フルバスタチン、ロスバスタチン、シンバスタチン、その他)、流通経路別(小売薬局、病院内薬局、オンライン薬局)、適応症別(家族性複合型高脂血症、家族性欠陥アポリポ蛋白B血症、3型高脂血症、家族性高トリグリセリド血症、ヘテロ接合性家族性高コレステロール血症、その他)
• レポートコード:TPM-B04233お問い合わせ(見積依頼・ご注文・質問)